The Dumont-UCLA Liver Cancer Center is presented as the site of a consequential 2001 liver transplant for Tadamasa Goto, a Japanese organized-crime leader whose route to treatment involved an FBI-mediated visa and raised unresolved questions about organ allocation and the origins of payments. The account distinguishes the medical care delivered there from the separate, unsettled questions of what the center knew about its patients and their finances.

Setting and Transplant

In January or February 2001, doctors at Showa University told Goto that he would die without a transplant soon. He had hepatitis C and a heart condition, and was considered a very unlikely candidate for a liver transplant in Japan. The transplant took place at the Dumont-UCLA Liver Cancer Center on July 5, 2001, after Goto obtained permission to enter the United States.

The reported cost varied substantially. Adelstein’s early information placed the amount Goto allegedly spent between about $1 million and $3 million; Goto later told an associate that the total was $3 million. Police reports listed $1 million and speculated that Goto’s doctor received $100,000 for each visit to Japan, usually at the Imperial Hotel. The account also notes that some hospital-expense money was sent from Japan to the United States through the Tokyo branch of a Las Vegas casino. These figures and routes are reported as allegations or estimates, not as a definitive accounting of the center’s charges.

Visa and Intelligence Deal

In April 2001, Goto approached the FBI through Hoshi Hitoshi, a former political fixer with connections to the Liberal Democratic Party. The FBI wanted information about prominent yakuza because Japan’s National Police Agency had declined to share such information, citing privacy concerns. Goto offered a comprehensive list of Yamaguchi-gumi members, associated front companies and financial institutions, as well as information about North Korean activities.

In exchange, Goto sought a U.S. visa so he could receive a transplant at UCLA. The account says the FBI pressured U.S. Immigration and Customs to issue the visa, which it did reluctantly; the medical center then performed the operation. Goto supplied only a fraction of the intelligence he had promised. After the transplant, he returned to Japan and did not speak to the FBI again. The center was thus the medical destination in a deal whose leverage came from law-enforcement access to the United States, not from the center itself.

Questions of Allocation and Oversight

The transplant acquired wider significance because Japan had a stringent transplant system, few donors, and relatively rare operations. Many Japanese people needing organs either left the country or died waiting. The account also suggests that Goto may not have been the only Japanese recipient with yakuza ties to receive a transplant at UCLA; Adelstein believed there were probably three others.

UCLA and Dr. Busuttil said they did not make moral judgments about patients and treated them according to medical need. It was never proven that either knew at the time of the transplants that any patient had ties to the Japanese mafia. They did not explicitly deny knowing of such ties, but declined to address what they knew and when. An investigation by the U.S. Centers for Medicare and Medicaid Services and UCLA found no evidence of improper conduct. The account therefore leaves distinct questions open: whether the allocation was fair, what the medical team knew, and whether the patients’ criminal backgrounds should have affected their treatment.

Possible Financial Implications

Federal law-enforcement sources told Adelstein that international money laundering can involve moving criminal proceeds from overseas into the United States. Because yakuza commonly obtain money through criminal activity, they said there was at least a possibility that some payment to UCLA by one or more of the four Japanese men with yakuza ties came from illegal activity in Japan. This was presented as a possibility, not a proven finding: Adelstein knew of no money-laundering investigation into the men, and such an inquiry would require Japanese authorities’ assistance.

The center’s significance in the narrative lies in this unresolved intersection of clinical care, scarce transplant resources, and cross-border finance. The available account records no finding that the center or its staff acted improperly; it also cannot settle what they knew about the patients or the source of payments. Those limits keep medical treatment, institutional responsibility, and possible criminal financing analytically separate rather than treating one as proof of another.